Sonoclear

Executive Summary

Sonoclear is a Norwegian medical device company addressing a critical need in neurosurgery: improving intraoperative visualization of brain tumors during resection. The company's patented SonoClear System is a sterile, advanced acoustic couplant that enhances ultrasound imaging clarity, enabling neurosurgeons to better distinguish residual tumor from healthy brain tissue. This technology aims to reduce the risk of neurological deficits by providing real-time, high-contrast images, potentially improving patient outcomes and surgical precision. Founded in 2016 and based in Oslo, Sonoclear operates at the intersection of oncology and medical devices, targeting a significant unmet need in brain cancer surgery where incomplete resection often leads to recurrence. While the company has not disclosed funding or commercial milestones, its focused approach and reliance on established ultrasound platforms could facilitate relatively straightforward adoption if clinical validation is achieved. The early-stage nature and lack of public pipeline details contribute to the conviction score being moderate.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical trial results for the SonoClear System60% success
• Q2 2027CE mark approval for European market entry50% success
• TBDStrategic partnership with a leading neurosurgery device distributor40% success